NCT04321421View on ClinicalTrials.gov

Hyperimmune Plasma for Critical Patients With COVID-19

NACompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

April 28, 2020

Study Completion Date

May 7, 2020

Conditions
COVID-19
Interventions
OTHER

hyperimmune plasma

administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5

Trial Locations (2)

27100

Catherine Klersy, Pavia

46100

Ospedale Asst Carlo Poma Mantova, Mantova

All Listed Sponsors
collaborator

OSPEDALE CARLO POMA ASST MANTOVA

UNKNOWN

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT04321421 - Hyperimmune Plasma for Critical Patients With COVID-19 | Biotech Hunter | Biotech Hunter